Evidence map›Paper›PMID 28518058›Full record

ArticleIET systems biology2017

Prediction of NSCLC recurrence from microarray data with GEP.

Russul Al-Anni, Jingyu Hou, Rana Dhia'a Abdu-Aljabar, Yong Xiang

Open access · greenAbstract read
In one paragraph

Article in IET systems biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Russul Al-AnniSchool of Information Technology, Deakin University, Victoria, Australia. ralanni@deakin.edu.au.
Jingyu HouSchool of Information Technology, Deakin University, Victoria, Australia.
Rana Dhia'a Abdu-AljabarInformation Engineering College, Al-Nahrain University, Baghdad, Iraq.
Yong XiangSchool of Information Technology, Deakin University, Victoria, Australia.
Deakin University · AUNahrain University · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is one of the deadliest diseases in the world. Non-small cell lung cancer (NSCLC) is the most common and dangerous type of lung cancer. Despite the fact that NSCLC is preventable and curable for some cases if diagnosed at early stages, the vast majority of patients are diagnosed very late. Furthermore, NSCLC usually recurs sometime after treatment. Therefore, it is of paramount importance to predict NSCLC recurrence, so that specific and suitable treatments can be sought. Nonetheless, conventional methods of predicting cancer recurrence rely solely on histopathology data and predictions are not reliable in many cases. The microarray gene expression (GE) technology provides a promising and reliable way to predict NSCLC recurrence by analysing the GE of sample cells. This study proposes a new model from GE programming to use microarray datasets for NSCLC recurrence prediction. To this end, the authors also propose a hybrid method to rank and select relevant prognostic genes that are related to NSCLC recurrence prediction. The proposed model was evaluated on real NSCLC microarray datasets and compared with other representational models. The results demonstrated the effectiveness of the proposed model.

Indexed as

Neoplasm Recurrence, LocalAlgorithmsArea Under CurveCarcinoma, Non-Small-Cell LungDatabases, GeneticGene Expression ProfilingHumansLung NeoplasmsOligonucleotide Array Sequence AnalysisPredictive Value of TestsPrognosisProteomicsReproducibility of ResultsROC CurveSensitivity and Specificity

Identifiers

PMID28518058
PMCPMC8687152
OpenAlexW2581120750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.